Cardiovascular Magnetic Resonance Versus Histopathologic Study for Diagnosis of Benign and Malignant Cardiac Tumours: A Systematic Review and Meta-Analysis.
Sandra Nóbrega, Catarina Martins da Costa, Ana Filipa Amador, Sofia Justo, Elisabete Martins
{"title":"Cardiovascular Magnetic Resonance Versus Histopathologic Study for Diagnosis of Benign and Malignant Cardiac Tumours: A Systematic Review and Meta-Analysis.","authors":"Sandra Nóbrega, Catarina Martins da Costa, Ana Filipa Amador, Sofia Justo, Elisabete Martins","doi":"10.4250/jcvi.2023.0028","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The gold standard for diagnosis of cardiac tumours is histopathological examination. Cardiovascular magnetic resonance (CMR) is a valuable non-invasive, radiation-free tool for identifying and characterizing cardiac tumours. Our aim is to understand CMR diagnosis of cardiac tumours by distinguishing benign vs. malignant tumours compared to the gold standard.</p><p><strong>Methods: </strong>A systematic search was performed in the PubMed, Web of Science, and Scopus databases up to December 2022, and the results were reviewed by 2 independent investigators. Studies reporting CMR diagnosis were included in a meta-analysis, and pooled measures were obtained. The risk of bias was assessed using the Quality Assessment Tools from the National Institutes of Health.</p><p><strong>Results: </strong>A total of 2,321 results was obtained; 10 studies were eligible, including one identified by citation search. Eight studies were included in the meta-analysis, which presented a pooled sensitivity of 93% and specificity of 94%, a diagnostic odds ratio of 185, and an area under the curve of 0.98 for CMR diagnosis of benign vs. malignant tumours. Additionally, 4 studies evaluated whether CMR diagnosis of cardiac tumours matched specific histopathological subtypes, with 73.6% achieving the correct diagnosis.</p><p><strong>Conclusions: </strong>To the best of our knowledge, this is the first published systematic review on CMR diagnosis of cardiac tumours. Compared to histopathological results, the ability to discriminate benign from malignant tumours was good but not outstanding. However, significant heterogeneity may have had an impact on our findings.</p>","PeriodicalId":15229,"journal":{"name":"Journal of Cardiovascular Imaging","volume":"31 4","pages":"159-168"},"PeriodicalIF":0.0000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10622638/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cardiovascular Imaging","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4250/jcvi.2023.0028","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The gold standard for diagnosis of cardiac tumours is histopathological examination. Cardiovascular magnetic resonance (CMR) is a valuable non-invasive, radiation-free tool for identifying and characterizing cardiac tumours. Our aim is to understand CMR diagnosis of cardiac tumours by distinguishing benign vs. malignant tumours compared to the gold standard.
Methods: A systematic search was performed in the PubMed, Web of Science, and Scopus databases up to December 2022, and the results were reviewed by 2 independent investigators. Studies reporting CMR diagnosis were included in a meta-analysis, and pooled measures were obtained. The risk of bias was assessed using the Quality Assessment Tools from the National Institutes of Health.
Results: A total of 2,321 results was obtained; 10 studies were eligible, including one identified by citation search. Eight studies were included in the meta-analysis, which presented a pooled sensitivity of 93% and specificity of 94%, a diagnostic odds ratio of 185, and an area under the curve of 0.98 for CMR diagnosis of benign vs. malignant tumours. Additionally, 4 studies evaluated whether CMR diagnosis of cardiac tumours matched specific histopathological subtypes, with 73.6% achieving the correct diagnosis.
Conclusions: To the best of our knowledge, this is the first published systematic review on CMR diagnosis of cardiac tumours. Compared to histopathological results, the ability to discriminate benign from malignant tumours was good but not outstanding. However, significant heterogeneity may have had an impact on our findings.
背景:诊断心脏肿瘤的金标准是组织病理学检查。心血管磁共振(CMR)是一种有价值的非侵入性、无辐射的工具,用于识别和表征心脏肿瘤。我们的目的是通过与金标准相比区分良性和恶性肿瘤来了解心脏肿瘤的CMR诊断。方法:截至2022年12月,在PubMed、Web of Science和Scopus数据库中进行系统搜索,结果由2名独立研究人员审查。报告CMR诊断的研究被纳入荟萃分析,并获得汇总指标。使用美国国立卫生研究院的质量评估工具对偏倚风险进行评估。结果:共获得2321个结果;10项研究符合条件,其中一项通过引文检索确定。荟萃分析中包括8项研究,其合并敏感性为93%,特异性为94%,诊断优势比为185,良性肿瘤与恶性肿瘤的CMR诊断曲线下面积为0.98。此外,4项研究评估了心脏肿瘤的CMR诊断是否符合特定的组织病理学亚型,73.6%的研究获得了正确诊断。结论:据我们所知,这是第一篇发表的关于心脏肿瘤CMR诊断的系统综述。与组织病理学结果相比,区分良性和恶性肿瘤的能力很好,但并不突出。然而,显著的异质性可能对我们的发现产生了影响。